Park, Hee Ho Kim, Hong Nam Kim, Hyelim Yoo, Youngbum Shin, Hyosoo Choi, Eun Young Bae, Jong-Sup Lee, Wonhwa 2024-01-19T17:04:38Z 2024-01-19T17:04:38Z 2021-09-05 2020-07 2375-2548 https://pubs.kist.re.kr/handle/201004/118467 The outbreak of the highly contagious and deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19), has posed a serious threat to public health across the globe, calling for the development of effective diagnostic markers and therapeutics. Here, we report a highly reliable severity diagnostic biomarker, acetylated 676th lysine transforming growth factor-beta-induced protein (TGFBIp K676Ac). TGFBIp K676Ac was consistently elevated in the blood of patients with SARS-CoV-2 pneumonia (n = 113), especially in patients in the intensive care unit (ICU) compared to non-ICU patients. Patients' blood samples showed increased cytokines and lymphopenia, which are exemplary indicators of SARS-CoV-2 pneumonia. Treatment with TGFBIp neutralizing antibodies suppressed the cytokine storm. The increased level of TGFBIp K676Ac in ICU patients suggests the promise of this protein as a reliable severity diagnostic biomarker for severe SARS-CoV-2 disease. English AMER ASSOC ADVANCEMENT SCIENCE COVID-19 PNEUMONIA CYTOKINE STORM BETA ACTIVATION PROTEIN Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia Article 10.1126/sciadv.abc1564 1 SCIENCE ADVANCES, v.6, no.31 SCIENCE ADVANCES 6 31 scie scopus 000556543100043 2-s2.0-85091129608 Multidisciplinary Sciences Science & Technology - Other Topics Article COVID-19 PNEUMONIA CYTOKINE STORM BETA ACTIVATION PROTEIN